Aleksandra V. Androsova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleksandra V. Androsova has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Rashida V. Orlova
St. Petersburg City Clinical Oncology Dispensary; St. Petersburg State University
16 shared publications - Svetlana I. Kutukova
First Pavlov University, Ministry of Health of Russia
15 shared publications - Natalia P. Beliak
St. Petersburg State University; City Clinical Oncology Dispensary
11 shared publications - Anastasiya K. Ivanova
St. Petersburg City Clinical Oncology Dispensary
6 shared publications - Eldar E. Topuzov
City Clinical Oncological Dispensary; I. I. Mechnikov North-West State Medical University, Ministry of Health of Russia
4 shared publications - Inna V. Avramenko
St. Petersburg City Clinical Oncology Dispensary
4 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (1) , 51-60
Anaemia during targeted anticancer therapy: pathogenesis, clinical features and modern correction approaches
Aim. To systematise current data on the mechanisms of anaemia development with major targeted anticancer drug classes, evaluate its impact on quality of life and summarise modern correction approaches. Materials and methods. A narrative literature review was performed searching PubMed, eLIBRARY and Cochrane Library with no date restrictions. Randomised clinical trials, meta-analyses, pharmacovigilance studies and current clinical guidelines (ESMO, ASCO/ASH) were analysed for the following drug classes: antibody–drug conjugates (ADCs), PARP inhibitors (PARPi), tyrosine kinase inhibitors and immune checkpoint inhibitors. Results. Anaemia occurs in 30–80 % of cancer patients and represents an independent prognostic factor for worse overall survival. ADC haematological toxicity is off-target and payload-driven: conjugates based on monomethylauristatin E carry the highest rates of severe anaemia. PARPi cause anaemia as a class effect via disruption of PARP-2-dependent erythroid differentiation. Tyrosine kinase inhibitors exert haematotoxicity through molecularly specific pathways, including disruption of erythrocyte membrane integrity. Immune checkpoint inhibitors are associated with immune-mediated haemolytic anaemia and aplastic syndrome. Among correction approaches, intravenous iron preparations and sucrosomial iron overcome the hepcidin-mediated functional block unachievable with classical oral salts. Erythropoiesis-stimulating agents are indicated under strict conditions given thromboembolic risk and potential immunosuppressive effects on the tumour microenvironment. Conclusion. Pathogenetically sound correction of anaemia during targeted therapy requires a differentiated approach accounting for the development mechanism, type of iron deficiency and targeted agent class. Blood count monitoring no later than 2 weeks from the first cycle start is mandatory for patients receiving ADCs, PARPi and immune checkpoint inhibitors.
- 26 June 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (1) , 51-60
Open AccessAnaemia during targeted anticancer therapy: pathogenesis, clinical features and modern correction approaches
Aim. To systematise current data on the mechanisms of anaemia development with major targeted anticancer drug classes, evaluate its impact on quality of life and summarise modern correction approaches. Materials and methods. A narrative literature review was performed searching PubMed, eLIBRARY and Cochrane Library with no date restrictions. Randomised clinical trials, meta-analyses, pharmacovigilance studies and current clinical guidelines (ESMO, ASCO/ASH) were analysed for the following drug classes: antibody–drug conjugates (ADCs), PARP inhibitors (PARPi), tyrosine kinase inhibitors and immune checkpoint inhibitors. Results. Anaemia occurs in 30–80 % of cancer patients and represents an independent prognostic factor for worse overall survival. ADC haematological toxicity is off-target and payload-driven: conjugates based on monomethylauristatin E carry the highest rates of severe anaemia. PARPi cause anaemia as a class effect via disruption of PARP-2-dependent erythroid differentiation. Tyrosine kinase inhibitors exert haematotoxicity through molecularly specific pathways, including disruption of erythrocyte membrane integrity. Immune checkpoint inhibitors are associated with immune-mediated haemolytic anaemia and aplastic syndrome. Among correction approaches, intravenous iron preparations and sucrosomial iron overcome the hepcidin-mediated functional block unachievable with classical oral salts. Erythropoiesis-stimulating agents are indicated under strict conditions given thromboembolic risk and potential immunosuppressive effects on the tumour microenvironment. Conclusion. Pathogenetically sound correction of anaemia during targeted therapy requires a differentiated approach accounting for the development mechanism, type of iron deficiency and targeted agent class. Blood count monitoring no later than 2 weeks from the first cycle start is mandatory for patients receiving ADCs, PARPi and immune checkpoint inhibitors.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3)
Strategies to overcome endocrine resistance in HR+/HER2- metastatic breast cancer: a real-world data
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the standard of care for HR+/HER2- metastatic breast cancer (mBC). However, the comparative effectiveness of different agents within this class in real-world clinical practice (RWCP) is insufficiently studied, particularly in the Russian population. Objective. To analyze the efficacy and safety of various iCDK4/6 (palbociclib and ribociclib) in real clinical practice at the St. Petersburg City Clinical Oncology Dispensary. Material and methods. A single-center retrospective cohort study with elements of prospective data collection was conducted. The analysis included 815 patients who received CDK4/6is in combination with endocrine therapy between January 2019 and March 2023. Progression-free survival (PFS), objective response rate, and univariate and multivariate analyses of various clinical and morphological factors influencing treatment efficacy were assessed. Propensity score matching (PSM) was used to minimize systematic bias when comparing palbociclib and ribociclib. Results. The median PFS in the overall population was 24.0 months (95% CI 20.2—27.8). In multivariate analysis, the presence of liver metastases (HR 1.95; p<0.001) and administration of CDK4/6i therapy in the second and subsequent lines (HR 1.34; p<0.001) were independent unfavorable prognostic factors. After PSM (n=174), the palbociclib and ribociclib groups were comparable in baseline characteristics; median PFS was 22 and 24 months, respectively (log-rank p=0.808). The objective response rate was higher in the palbociclib group (37.9% vs. 9.2%; p<0.001). Conclusion. In real-world clinical practice, CDK4/6 inhibitors demonstrate high effectiveness comparable to the results of registration trials. Palbociclib and ribociclib have similar PFS outcomes. Key factors worsening prognosis are visceral metastases (especially liver involvement) and later lines of therapy.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3)
Strategies to overcome endocrine resistance in HR+/HER2- metastatic breast cancer: a real-world data
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the standard of care for HR+/HER2- metastatic breast cancer (mBC). However, the comparative effectiveness of different agents within this class in real-world clinical practice (RWCP) is insufficiently studied, particularly in the Russian population. Objective. To analyze the efficacy and safety of various iCDK4/6 (palbociclib and ribociclib) in real clinical practice at the St. Petersburg City Clinical Oncology Dispensary. Material and methods. A single-center retrospective cohort study with elements of prospective data collection was conducted. The analysis included 815 patients who received CDK4/6is in combination with endocrine therapy between January 2019 and March 2023. Progression-free survival (PFS), objective response rate, and univariate and multivariate analyses of various clinical and morphological factors influencing treatment efficacy were assessed. Propensity score matching (PSM) was used to minimize systematic bias when comparing palbociclib and ribociclib. Results. The median PFS in the overall population was 24.0 months (95% CI 20.2—27.8). In multivariate analysis, the presence of liver metastases (HR 1.95; p<0.001) and administration of CDK4/6i therapy in the second and subsequent lines (HR 1.34; p<0.001) were independent unfavorable prognostic factors. After PSM (n=174), the palbociclib and ribociclib groups were comparable in baseline characteristics; median PFS was 22 and 24 months, respectively (log-rank p=0.808). The objective response rate was higher in the palbociclib group (37.9% vs. 9.2%; p<0.001). Conclusion. In real-world clinical practice, CDK4/6 inhibitors demonstrate high effectiveness comparable to the results of registration trials. Palbociclib and ribociclib have similar PFS outcomes. Key factors worsening prognosis are visceral metastases (especially liver involvement) and later lines of therapy.
- Open Access
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 26-32
Efficacy of olaparib maintenance therapy in patients with BRCA-mutated ovarian cancer: a retrospective analysis of real-world clinical practice data
Aim: To evaluate the efficacy of olaparib maintenance therapy in real-world clinical practice in patients with BRCA-mutated ovarian cancer. Objectives: To evaluate progression-free survival (PFS) by olaparib therapy line. To determine the predictive value of the level of the cancer marker CA-125 before therapy. To analyze the incidence of adverse events requiring dose reduction or drug discontinuation. Materials and Methods: A retrospective analysis included data of 110 patients with Stage I–IV BRCA1 / 2 mutated high-grade serous ovarian cancer, who received olaparib maintenance therapy at the St. Petersburg Municipal Clinical Oncology Dispensary from 2020 to 2024. Patients were stratified into three groups: first-line olaparib (1L, n = 64), olaparib after the first recurrence (AR1, n = 24), and olaparib after two or more recurrences (AR2+ , n = 22). Statistical analysis included Kaplan-Meier survival estimates and multivariate analysis using Cox regression. Results: The median PFS was not reached in the 1L group. In the AR1 and AR2+ groups, the median PFS was 49 and 20 months, respectively (p < 0.001). An elevated baseline CA-125 level (> 35 U / mL) before initiation of olaparib therapy was associated with a statistically significant 3.2-fold increase in the risk of progression (odds ratio [OR] 3.2; 95 % CI 1.5–6.8; p = 0.003). Toxicities requiring dose adjustment were reported in 14.1 %, 12.5 %, and 13.6 % of patients in the 1L, AR1, and AR2+ groups, respectively. Conclusions: Olaparib maintenance therapy demonstrated high clinical efficacy and a manageable safety profile in real-world settings, with the greatest benefit observed in the first-line setting. Elevated pre-treatment CA-125 levels (> 35 U / mL) are an unfavorable prognostic marker.
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 26-32
Open AccessEfficacy of olaparib maintenance therapy in patients with BRCA-mutated ovarian cancer: a retrospective analysis of real-world clinical practice data
Aim: To evaluate the efficacy of olaparib maintenance therapy in real-world clinical practice in patients with BRCA-mutated ovarian cancer. Objectives: To evaluate progression-free survival (PFS) by olaparib therapy line. To determine the predictive value of the level of the cancer marker CA-125 before therapy. To analyze the incidence of adverse events requiring dose reduction or drug discontinuation. Materials and Methods: A retrospective analysis included data of 110 patients with Stage I–IV BRCA1 / 2 mutated high-grade serous ovarian cancer, who received olaparib maintenance therapy at the St. Petersburg Municipal Clinical Oncology Dispensary from 2020 to 2024. Patients were stratified into three groups: first-line olaparib (1L, n = 64), olaparib after the first recurrence (AR1, n = 24), and olaparib after two or more recurrences (AR2+ , n = 22). Statistical analysis included Kaplan-Meier survival estimates and multivariate analysis using Cox regression. Results: The median PFS was not reached in the 1L group. In the AR1 and AR2+ groups, the median PFS was 49 and 20 months, respectively (p < 0.001). An elevated baseline CA-125 level (> 35 U / mL) before initiation of olaparib therapy was associated with a statistically significant 3.2-fold increase in the risk of progression (odds ratio [OR] 3.2; 95 % CI 1.5–6.8; p = 0.003). Toxicities requiring dose adjustment were reported in 14.1 %, 12.5 %, and 13.6 % of patients in the 1L, AR1, and AR2+ groups, respectively. Conclusions: Olaparib maintenance therapy demonstrated high clinical efficacy and a manageable safety profile in real-world settings, with the greatest benefit observed in the first-line setting. Elevated pre-treatment CA-125 levels (> 35 U / mL) are an unfavorable prognostic marker.
- 28 January 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (3)
Modern international guidelines for the management of patients after completion of breast cancer treatment: an evidencebased review
Background. Advances in breast cancer (BC) treatment have led to a large and growing population of survivors. This necessitates a clinical paradigm shift from a sole focus on survival to the comprehensive management of long-term health and quality of life. Objective. To critically analyze and synthesize current evidence-based data on key aspects of post-treatment BC care, emphasizing the transition from passive surveillance to proactive strategies for rehabilitation and secondary prevention. Materials and methods. A systematic analysis of data from key randomized clinical trials (RCTs), meta-analyses (Cochrane, EBCTCG), and clinical guidelines (ESMO, NCCN) was conducted. The review covers the efficacy of follow-up protocols, the impact of lifestyle factors, methods for managing endocrine therapy complications, and modern approaches to fertility preservation. Results. The analysis reveals a scientific consensus on the inefficacy of intensive instrumental screening in asymptomatic patients. Conversely, the role of lifestyle modification is strongly evidenced, with body weight control and regular physical activity being key factors in reducing the risk of recurrence and mortality. Managing long-term complications of endocrine therapy, such as osteoporosis and genitourinary syndrome, requires a proactive approach, including the use of bone-modifying agents (which also possess antitumor effects) and safe methods of local hormonal treatment. The POSITIVE trial represents a breakthrough in oncofertility, proving the safety of temporarily interrupting therapy to pursue pregnancy, which fundamentally changes counseling for young patients. Conclusion. The modern concept of BC survivorship care demands a shift towards personalized survivorship care plans. These plans must integrate evidence-based surveillance strategies, proactive management of side effects, mandatory screening and correction of psychological distress, and active patient engagement in lifestyle modification. Future research should focus on developing effective models for implementing these comprehensive approaches into routine clinical practice.
- 28 January 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (3)
Modern international guidelines for the management of patients after completion of breast cancer treatment: an evidencebased review
Background. Advances in breast cancer (BC) treatment have led to a large and growing population of survivors. This necessitates a clinical paradigm shift from a sole focus on survival to the comprehensive management of long-term health and quality of life. Objective. To critically analyze and synthesize current evidence-based data on key aspects of post-treatment BC care, emphasizing the transition from passive surveillance to proactive strategies for rehabilitation and secondary prevention. Materials and methods. A systematic analysis of data from key randomized clinical trials (RCTs), meta-analyses (Cochrane, EBCTCG), and clinical guidelines (ESMO, NCCN) was conducted. The review covers the efficacy of follow-up protocols, the impact of lifestyle factors, methods for managing endocrine therapy complications, and modern approaches to fertility preservation. Results. The analysis reveals a scientific consensus on the inefficacy of intensive instrumental screening in asymptomatic patients. Conversely, the role of lifestyle modification is strongly evidenced, with body weight control and regular physical activity being key factors in reducing the risk of recurrence and mortality. Managing long-term complications of endocrine therapy, such as osteoporosis and genitourinary syndrome, requires a proactive approach, including the use of bone-modifying agents (which also possess antitumor effects) and safe methods of local hormonal treatment. The POSITIVE trial represents a breakthrough in oncofertility, proving the safety of temporarily interrupting therapy to pursue pregnancy, which fundamentally changes counseling for young patients. Conclusion. The modern concept of BC survivorship care demands a shift towards personalized survivorship care plans. These plans must integrate evidence-based surveillance strategies, proactive management of side effects, mandatory screening and correction of psychological distress, and active patient engagement in lifestyle modification. Future research should focus on developing effective models for implementing these comprehensive approaches into routine clinical practice.
- Open Access
- 10 October 2025
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (2) , 15-24
Toxicity profile of cyclin-dependent kinase inhibitors in real-time clinical practice
Background. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a standard of care for ER-positive/HER2-negative metastatic breast cancer (MBC), yet real-world safety may differ from randomized controlled trials (RCTs).Objective. To assess the safety of palbociclib and ribociclib combined with endocrine therapy in routine clinical practice.Methods. Prospective, open-label, single-center, non-randomized study including 815 patients treated between April 2020 and October 2023. Palbociclib cohort: n=365 (125 mg QD, 21/7); ribociclib cohort: n=450 (600 mg QD, 21/7). Adverse events (AEs) were graded by CTCAE v5.0; standard statistics with pResults. Any-grade AEs occurred in 33.4% (palbociclib) and 24.0% (ribociclib). Toxicity spectra differed: palbociclib was associated mainly with hematologic AEs—neutropenia in 112/365 (30.7%), including grade 3–4 in 37/365 (10.1%); febrile neutropenia in 1/365 (0.3%). Ribociclib showed predominantly non-hematologic AEs — asthenia in 34/450 (7.6%) (mostly grade ≤2); ALT/AST elevations in 16/450 (3.6%); QT interval prolongation in 2/450 (0.4%). Diarrhea and rash were uncommon in both cohorts. Dose reductions implemented for toxicity did not compromise progression-free survival in within-group comparisons.Conclusions. In real-world practice, CDK4/6 inhibitors demonstrate favorable tolerability with predictable, distinct toxicity patterns (hematologic with palbociclib; mainly non-hematologic with ribociclib), supporting individualized drug selection and safety monitoring strategies.
- 10 October 2025
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (2) , 15-24
Open AccessToxicity profile of cyclin-dependent kinase inhibitors in real-time clinical practice
Background. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a standard of care for ER-positive/HER2-negative metastatic breast cancer (MBC), yet real-world safety may differ from randomized controlled trials (RCTs).Objective. To assess the safety of palbociclib and ribociclib combined with endocrine therapy in routine clinical practice.Methods. Prospective, open-label, single-center, non-randomized study including 815 patients treated between April 2020 and October 2023. Palbociclib cohort: n=365 (125 mg QD, 21/7); ribociclib cohort: n=450 (600 mg QD, 21/7). Adverse events (AEs) were graded by CTCAE v5.0; standard statistics with pResults. Any-grade AEs occurred in 33.4% (palbociclib) and 24.0% (ribociclib). Toxicity spectra differed: palbociclib was associated mainly with hematologic AEs—neutropenia in 112/365 (30.7%), including grade 3–4 in 37/365 (10.1%); febrile neutropenia in 1/365 (0.3%). Ribociclib showed predominantly non-hematologic AEs — asthenia in 34/450 (7.6%) (mostly grade ≤2); ALT/AST elevations in 16/450 (3.6%); QT interval prolongation in 2/450 (0.4%). Diarrhea and rash were uncommon in both cohorts. Dose reductions implemented for toxicity did not compromise progression-free survival in within-group comparisons.Conclusions. In real-world practice, CDK4/6 inhibitors demonstrate favorable tolerability with predictable, distinct toxicity patterns (hematologic with palbociclib; mainly non-hematologic with ribociclib), supporting individualized drug selection and safety monitoring strategies.
- Open Access
- 28 February 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (1)
Gastrointestinal Tract Tumors with Microsatellite Instability: A Single-Center Experience
Введение. Развитие микросателлитной нестабильности в результате герминативной или спорадической мутации в генах системы репарации ошибочно спаренных нуклеотидов (MMR) является ключевым звеном в запуске механизмов канцерогенеза посредством формирования опухолевых неоантигенов, представляющих собой мишени для Т-лимфоцитов, что, в конечном счете, обусловливает высокую иммуногенность данных опухолей и их чувствительность к ингибиторам контрольных точек иммунитета. Цель. Определение клинико-морфологических особенностей опухолей желудка, ободочной и прямой кишки с выявленной микросателлитной нестабильностью. Материалы и методы. В ретроспективный анализ было включено 76 пациентов с установленным dMMR (36 пациентов больных колоректальным раком и 42 пациента со злокачественными новообразованиями желудка). Результаты. Общими характеристиками для вышеописанных опухолей являются: местно-распространенный характер процесса (T3-T4, N2-N3), осложненное течение заболевания, превалирующее при иммуногистохимическом (ИГХ) тестировании выпадение белков РМS2, МLH1, прогрессирование и низкая частота достижения объективного ответа на фоне проводимой полихимиотерапией (ПХТ), высокая эффективность иммунотерапии (ИТ) в монорежиме или в комбинации с ПХТ (уровень контроля над заболеванием (65 % и 73,68 % для опухолей желудка и КРР соответственно)), медиана выживаемости без прогрессирования у пациентов, завершивших лечение ингибиторами контрольных точек, не достигнута как в группе рака желудка, так и в группе колоректального рака.
- 28 February 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (1)
Open AccessGastrointestinal Tract Tumors with Microsatellite Instability: A Single-Center Experience
Введение. Развитие микросателлитной нестабильности в результате герминативной или спорадической мутации в генах системы репарации ошибочно спаренных нуклеотидов (MMR) является ключевым звеном в запуске механизмов канцерогенеза посредством формирования опухолевых неоантигенов, представляющих собой мишени для Т-лимфоцитов, что, в конечном счете, обусловливает высокую иммуногенность данных опухолей и их чувствительность к ингибиторам контрольных точек иммунитета. Цель. Определение клинико-морфологических особенностей опухолей желудка, ободочной и прямой кишки с выявленной микросателлитной нестабильностью. Материалы и методы. В ретроспективный анализ было включено 76 пациентов с установленным dMMR (36 пациентов больных колоректальным раком и 42 пациента со злокачественными новообразованиями желудка). Результаты. Общими характеристиками для вышеописанных опухолей являются: местно-распространенный характер процесса (T3-T4, N2-N3), осложненное течение заболевания, превалирующее при иммуногистохимическом (ИГХ) тестировании выпадение белков РМS2, МLH1, прогрессирование и низкая частота достижения объективного ответа на фоне проводимой полихимиотерапией (ПХТ), высокая эффективность иммунотерапии (ИТ) в монорежиме или в комбинации с ПХТ (уровень контроля над заболеванием (65 % и 73,68 % для опухолей желудка и КРР соответственно)), медиана выживаемости без прогрессирования у пациентов, завершивших лечение ингибиторами контрольных точек, не достигнута как в группе рака желудка, так и в группе колоректального рака.
- Open Access
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Factors Influencing the Course of Neuroendocrine Tumors of the Gastrointestinal Tract
Введение. В связи с тем, что алгоритм лечения нейроэндокринных опухолей желудочно-кишечного тракта определяется только локализацией неоплазии и ориентирован на классификацию по степени дифференцировки, поиск дополнительных прогностических маркеров является актуальной задачей. Цель. Целью исследования является определение факторов неблагоприятного прогноза у пациентов с нейроэндокринными опухолями желудочно-кишечного тракта для повышения эффективности лечения. Материалы и методы. На начальном этапе проанализированы клинико-морфологические особенности 298 пациентов нейроэндокринными опухолями желудочно-кишечного тракта. На следующем этапе было проведено исследование влияния показателей периферической крови, факторов системного воспаления и индекса пролиферации (Ki-67) на течение нейроэндокринных опухолей желудочно-кишечного тракта (71 пациент). Также были оценены прогностическая значимость наличия сахарного диабета 2 типа, уровня глюкозы до начала лечения, индекса массы тела и карциноидного синдрома (34 пациента с сахарным диабетом 2 типа и 30 пациентов в группе контроля). Результаты. Удалось выявить факторы неблагоприятного прогноза течения и раннего прогрессирования НЭО ЖКТ: Ki-67 > 5 %, относительное число нейтрофилов > 58,30 %, относительное число лимфоцитов ≤ 30 %, нейтрофильно-лимфоцитарный индекс (НЛИ) > 1,85. Оптимальное пороговое значение количества факторов неблагоприятного прогноза в точке cut-off составило 2: наличие 2-х и более факторов неблагоприятного прогноза на момент первичной оценки негативно влияло на время без прогрессирования (ВБП) больных. Наличие у больного > 2-х факторов неблагоприятного прогноза течения заболевания увеличивало риск прогрессирования заболевания на 67 %: р = 0,0013; ОР = 1,67, 95 % ДИ 1,05-1,78. Заключение. Выявлены факторы неблагоприятного прогноза течения и раннего прогрессирования НЭО ЖКТ.
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Open AccessFactors Influencing the Course of Neuroendocrine Tumors of the Gastrointestinal Tract
Введение. В связи с тем, что алгоритм лечения нейроэндокринных опухолей желудочно-кишечного тракта определяется только локализацией неоплазии и ориентирован на классификацию по степени дифференцировки, поиск дополнительных прогностических маркеров является актуальной задачей. Цель. Целью исследования является определение факторов неблагоприятного прогноза у пациентов с нейроэндокринными опухолями желудочно-кишечного тракта для повышения эффективности лечения. Материалы и методы. На начальном этапе проанализированы клинико-морфологические особенности 298 пациентов нейроэндокринными опухолями желудочно-кишечного тракта. На следующем этапе было проведено исследование влияния показателей периферической крови, факторов системного воспаления и индекса пролиферации (Ki-67) на течение нейроэндокринных опухолей желудочно-кишечного тракта (71 пациент). Также были оценены прогностическая значимость наличия сахарного диабета 2 типа, уровня глюкозы до начала лечения, индекса массы тела и карциноидного синдрома (34 пациента с сахарным диабетом 2 типа и 30 пациентов в группе контроля). Результаты. Удалось выявить факторы неблагоприятного прогноза течения и раннего прогрессирования НЭО ЖКТ: Ki-67 > 5 %, относительное число нейтрофилов > 58,30 %, относительное число лимфоцитов ≤ 30 %, нейтрофильно-лимфоцитарный индекс (НЛИ) > 1,85. Оптимальное пороговое значение количества факторов неблагоприятного прогноза в точке cut-off составило 2: наличие 2-х и более факторов неблагоприятного прогноза на момент первичной оценки негативно влияло на время без прогрессирования (ВБП) больных. Наличие у больного > 2-х факторов неблагоприятного прогноза течения заболевания увеличивало риск прогрессирования заболевания на 67 %: р = 0,0013; ОР = 1,67, 95 % ДИ 1,05-1,78. Заключение. Выявлены факторы неблагоприятного прогноза течения и раннего прогрессирования НЭО ЖКТ.
- Open Access
- 18 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 49-55
Angiosarcoma of the breast (literature review and description of two clinical observations)
Breast angiosarcoma is a rare malignancy that accounts for less than 0.5% of all breast cancers. The disease is characterized by rapid growth, aggressive course, active dissemination of the process and poor response to treatment. The peculiarity of the disease lies in the complexity of diagnosing the process, since the clinical picture is not specific and often occurs under the guise of skin diseases such as eczema, atopic dermatitis, rosacea, etc. Also, the complexity of diagnosis is complemented by the lack of specific imaging methods, thanks to which it would be possible to diagnose angiosarcoma with high accuracy. The leading element of treatment is a combined approach, namely a combination of surgical excision, drug therapy and radiation. This article presents our own experience in managing a patient with angiosarcoma of the right breast, which arose 7 years after the treatment of breast carcinoma in the St. Petersburg City Clinical Oncology Center.
- 18 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 49-55
Open AccessAngiosarcoma of the breast (literature review and description of two clinical observations)
Breast angiosarcoma is a rare malignancy that accounts for less than 0.5% of all breast cancers. The disease is characterized by rapid growth, aggressive course, active dissemination of the process and poor response to treatment. The peculiarity of the disease lies in the complexity of diagnosing the process, since the clinical picture is not specific and often occurs under the guise of skin diseases such as eczema, atopic dermatitis, rosacea, etc. Also, the complexity of diagnosis is complemented by the lack of specific imaging methods, thanks to which it would be possible to diagnose angiosarcoma with high accuracy. The leading element of treatment is a combined approach, namely a combination of surgical excision, drug therapy and radiation. This article presents our own experience in managing a patient with angiosarcoma of the right breast, which arose 7 years after the treatment of breast carcinoma in the St. Petersburg City Clinical Oncology Center.
- Open Access
- 15 December 2024
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 1 (3) , 13-25
Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study
Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around the world, it is extremely important to address the issue of indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well as the scope and regimens of treatment. The article presents the results of our own study, considers the problems of toxicity and tolerability of dose-dense and standard NACT regimens.Aim. To study the tolerability of dose-dense and standard NACT regimens.Materials and methods. The prospective study included 109 patients. 53 patients received dose-dense NACT as preoperative treatment, 56 – the standard NACT regimen.Results. In dose-dense NACT, the frequency and severity of anemia (p = 0.038), hepatotoxicity (p 0.001), peripheral polyneuropathy (p 0.001) increased, but the frequency of delayed start of the cycle in general (p = 0.012) and delay due to neutropenia (p 0.001) decreased.Conclusion. When planning preventive chemotherapy in the treatment of breast cancer (NACT or adjuvant chemotherapy), it is necessary to take into account not only the oncological results in increasing recurrence-free and overall survival, but also the tolerability of therapy.
- 15 December 2024
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 1 (3) , 13-25
Open AccessTolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study
Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around the world, it is extremely important to address the issue of indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well as the scope and regimens of treatment. The article presents the results of our own study, considers the problems of toxicity and tolerability of dose-dense and standard NACT regimens.Aim. To study the tolerability of dose-dense and standard NACT regimens.Materials and methods. The prospective study included 109 patients. 53 patients received dose-dense NACT as preoperative treatment, 56 – the standard NACT regimen.Results. In dose-dense NACT, the frequency and severity of anemia (p = 0.038), hepatotoxicity (p 0.001), peripheral polyneuropathy (p 0.001) increased, but the frequency of delayed start of the cycle in general (p = 0.012) and delay due to neutropenia (p 0.001) decreased.Conclusion. When planning preventive chemotherapy in the treatment of breast cancer (NACT or adjuvant chemotherapy), it is necessary to take into account not only the oncological results in increasing recurrence-free and overall survival, but also the tolerability of therapy.
- Open Access
- 30 November 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (5)
Gastrointestinal Tract Tumors with Microsatellite Instability: A Single-Center Experience
Введение. Развитие микросателлитной нестабильности в результате герминативной или спорадической мутации в генах системы репарации ошибочно спаренных нуклеотидов (MMR) является ключевым звеном в запуске механизмов канцерогенеза посредством формирования опухолевых неоантигенов, представляющих собой мишени для Т-лимфоцитов, что, в конечном счете, обусловливает высокую иммуногенность данных опухолей и их чувствительность к ингибиторам контрольных точек иммунитета. Цель. Определение клинико-морфологических особенностей опухолей желудка, ободочной и прямой кишки с выявленной микросателлитной нестабильностью. Материалы и методы. В ретроспективный анализ было включено 76 пациентов с установленным dMMR (36 пациентов больных колоректальным раком и 42 пациента со злокачественными новообразованиями желудка). Результаты. Общими характеристиками для вышеописанных опухолей являются: местно-распространенный характер процесса (T3-T4, N2-N3), осложненное течение заболевания, превалирующее при иммуногистохимическом (ИГХ) тестировании выпадение белков РМS2, МLH1, прогрессирование и низкая частота достижения объективного ответа на фоне проводимой полихимиотерапией (ПХТ), высокая эффективность иммунотерапии (ИТ) в монорежиме или в комбинации с ПХТ (уровень контроля над заболеванием (65 % и 73,68 % для опухолей желудка и КРР соответственно)), медиана выживаемости без прогрессирования у пациентов, завершивших лечение ингибиторами контрольных точек, не достигнута как в группе рака желудка, так и в группе колоректального рака.
- 30 November 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (5)
Open AccessGastrointestinal Tract Tumors with Microsatellite Instability: A Single-Center Experience
Введение. Развитие микросателлитной нестабильности в результате герминативной или спорадической мутации в генах системы репарации ошибочно спаренных нуклеотидов (MMR) является ключевым звеном в запуске механизмов канцерогенеза посредством формирования опухолевых неоантигенов, представляющих собой мишени для Т-лимфоцитов, что, в конечном счете, обусловливает высокую иммуногенность данных опухолей и их чувствительность к ингибиторам контрольных точек иммунитета. Цель. Определение клинико-морфологических особенностей опухолей желудка, ободочной и прямой кишки с выявленной микросателлитной нестабильностью. Материалы и методы. В ретроспективный анализ было включено 76 пациентов с установленным dMMR (36 пациентов больных колоректальным раком и 42 пациента со злокачественными новообразованиями желудка). Результаты. Общими характеристиками для вышеописанных опухолей являются: местно-распространенный характер процесса (T3-T4, N2-N3), осложненное течение заболевания, превалирующее при иммуногистохимическом (ИГХ) тестировании выпадение белков РМS2, МLH1, прогрессирование и низкая частота достижения объективного ответа на фоне проводимой полихимиотерапией (ПХТ), высокая эффективность иммунотерапии (ИТ) в монорежиме или в комбинации с ПХТ (уровень контроля над заболеванием (65 % и 73,68 % для опухолей желудка и КРР соответственно)), медиана выживаемости без прогрессирования у пациентов, завершивших лечение ингибиторами контрольных точек, не достигнута как в группе рака желудка, так и в группе колоректального рака.